Relation between plasma antioxidant vitamin levels, adiposity and cardio-metabolic profile in adolescents: Effects of a multidisciplinary obesity programme by Guerendiain, M. et al.
lable at ScienceDirect
Clinical Nutrition xxx (2015) 1e9Contents lists avaiClinical Nutrition
journal homepage: ht tp: / /www.elsevier .com/locate/c lnuOriginal articleRelation between plasma antioxidant vitamin levels, adiposity and
cardio-metabolic profile in adolescents: Effects of a multidisciplinary
obesity programme
Marcela Guerendiain a, b, Jordi Mayneris-Perxachs a, Rosa Montes a, f,
Gemma Lopez-Belmonte c, Miguel Martín-Matillas d, e, Ana I. Castellote a, f,
Elena Martín-Bautista d, Amelia Martí f, g, J. Alfredo Martínez f, g, Luis Moreno h,
Jesús Mª Garagorri h, Julia W€arnberg i, Javier Caballero j, Ascension Marcos i,
M. Carmen Lopez-Sabater a, f, *, Cristina Campoy c, d, k, EVASYON Study Group
a Department of Nutrition and Food Science, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain
b University of the Republic, Montevideo, Uruguay
c Instituto de Investigacion Biosanitaria (Ibs Granada), Department of Paediatrics, University of Granada, Granada, Spain
d EURISTIKOS Excellence Centre for Paediatric Research, Granada, Spain
e Department of Physical Education and Sport, School of Sport Sciences, University of Granada, Spain
f CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlos III, Spain
g Department of Nutrition, Food Science, Physiology and Toxicology, University of Navarra, Pamplona, Spain
h Department of Paediatrics, Radiology and Physical Medicine, University of Zaragoza, Spain
i Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Spanish National Research Council (CSIC), Madrid,
Spain
j Biochemical Service, Hospital Reina Sofía, Cordoba, Spain
k CIBER de Epidemiología y Salud Pública (CIBERESP), Granada, Spaina r t i c l e i n f o
Article history:
Received 25 May 2015






Obese adolescentsAbbreviations: ApoA1, apolipoprotein A1; ApoB, a
pressure; FFM, fat free mass; FMI, fat mass index; HD
SBP, systolic blood pressure; TAG, triacylglycerols; UH
* Corresponding author. Department of Nutrition a
934024512.
E-mail address: mclopez@ub.edu (M.C. Lopez-Sab
http://dx.doi.org/10.1016/j.clnu.2015.11.001
0261-5614/© 2015 Elsevier Ltd and European Society
Please cite this article in press as: Guerendi
profile in adolescents: Effects of a multidiscs u m m a r y
Background & aims: In vivo and in vitro evidence suggests that antioxidant vitamins and carotenoids
may be key factors in the treatment and prevention of obesity and obesity-associated disorders. Hence,
the objective of the present study was to determine the relationship between plasma lipid-soluble
antioxidant vitamin and carotenoid levels and adiposity and cardio-metabolic risk markers in over-
weight and obese adolescents participating in a multidisciplinary weight loss programme.
Methods: A therapeutic programme was conducted with 103 adolescents aged 12e17 years old and
diagnosed with overweight or obesity. Plasma concentrations of a-tocopherol, retinol, b-carotene and
lycopene, anthropometric indicators of general and central adiposity, blood pressure and biochemical
parameters were analysed at baseline and at 2 and 6 months of treatment.
Results: Lipid-corrected retinol (P < 0.05), b-carotene (P ¼ 0.001) and a-tocopherol (P < 0.001) plasma
levels increased significantly, whereas lipid-corrected lycopene levels remained unaltered during the
treatment. Anthropometric indicators of adiposity (P < 0.001), blood pressure (P < 0.01) and biochemical
parameters (P < 0.05) decreased significantly, whereas fat free mass increased significantly (P < 0.001).
These clinical and biochemical improvements were related to changes in plasma lipid-corrected anti-
oxidant vitamin and carotenoid levels. The adolescents who experienced the greatest weight loss also
showed the largest decrease in anthropometric indicators of adiposity and biochemical parameters and
the highest increase in fat free mass. Weight loss in these adolescents was related to an increase in
plasma levels of lipid-corrected a-tocopherol (P ¼ 0.001), b-carotene (P ¼ 0.034) and lycopene
(P ¼ 0.019).polipoprotein B; BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular diseases; DBP, diastolic blood
L, high density lipoprotein; LC, lipid-corrected; LDL, low density lipoprotein; SDS-BMI, BMI standard deviation score;
PLC, Ultra High Performance Liquid Chromatography.
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profile in adolescents: Effects of a multidiscConclusions: Plasma lipid-soluble antioxidant vitamin and carotenoid levels are associated with reduced
adiposity, greater weight loss and an improved cardio-metabolic profile in overweight and obese
adolescents.
© 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.1. Introduction
The prevalence of obesity has increased in recent decades and
this disorder is now considered a 21st century epidemic. It is the
most common nutritional issue among children and adolescents in
developed countries, but has also reached alarming values in
developing countries [1].
Obesity is an important risk factor of cardiovascular diseases
(CVD) and is strongly related to other cardiovascular risk factors
such as hypertension, diabetes, dyslipidemia and inflammation [2],
therefore onset of obesity is of particular concern in children and
adolescents [3,4]. It has been found that similar to obese adults,
obese childrenpresent a higher degree of oxidative stress than their
normal weight counterparts [5]. Moreover, obesity is linked to
decreased plasma antioxidant vitamin levels and antioxidant ca-
pacity [6]. Thus, the scientific evidence suggests that antioxidant
vitamins and carotenoids may be key factors in the treatment and
prevention of obesity and obesity-associated disorders.
Recent studies have indicated that vitamin A [7] and b-carotene
[8] are important regulators of body fat reserves. As an example,
retinoic acid derived from vitamin A and b-carotene is involved in
the expression of lipogenic transcription factors [7,8]. Furthermore,
it has been observed that vitamin A and carotenoids present anti-
inflammatory properties [9e11] and have an antioxidant action
[10e12]. Within the carotenoids, lycopene has the highest antiox-
idant capacity compared to a-tocopherol and b-carotene [13].
Numerous epidemiological studies have shown a significant in-
verse association between plasma or tissue lycopene levels and the
incidence of CVD or CVD risk factors (atherosclerosis, hypertension,
diabetes, metabolic syndrome, inflammation and oxidative stress)
[12]. Also, it has been suggested that lycopene can prevent
inflammation [11] by decreasing transcription factor activation and
secretion of inflammatory markers in adipose tissue [9].
Vitamin E is another lipid-soluble vitamin that presents a high
antioxidant capacity [13,14]. Recently, it was found that vitamin E is
involved in the expression of genes associated with glucose and
lipid metabolism [15,16]. In addition, some authors have observed a
lower incidence of chronic disease and cardiovascular events when
dietary intake of vitamin E is increased [14].
The study of changes in anthropometric and metabolic param-
eters and plasma antioxidant levels in obese children is useful in
order to determine their associations and establish dietary regimes
aimed at reducing the prevalence of paediatric obesity and asso-
ciated pathologies. Nonetheless, to our knowledge, few studies
have focussed in this issue. Hence, the objective of the present
study was to determine the relationship between plasma levels of
a-tocopherol, retinol, b-carotene and lycopene and adiposity and
cardio-metabolic riskmarkers in overweight and obese adolescents
participating in a multidisciplinary weight loss programme.2. Materials and methods
2.1. Ethics statement
This study was conducted in accordancewith the ethical rules of
the Helsinki Declaration (Hong Kong revision, September 1989,ain M, et al., Relation betwee
iplinary obesity programme,Edinburgh revision 2000 and Korea revision 2008), the European
Economic Community (EEC) Good Clinical Practice guidelines
(document 111/3976/88 of July 1990) and current Spanish law,
which regulates clinical research on humans (Royal Decree 561/
1993 regarding clinical trials). Written informed consent was ob-
tained from all adolescents and their parents, and the study was
approved by the local ethics committees. Data obtained during the
intervention was confidential and restricted to the participating
investigators.
2.2. Participants and study design
The study sample used in the present analysis comprised 103
adolescents aged 12e17 years old and diagnosed with overweight
and obesity at four hospitals located in different Spanish cities
(Granada, Madrid, Pamplona and Zaragoza). The inclusion criteria
were as follows: to be overweight or obese as defined by Interna-
tional Obesity Task Force age- and sex-specific body mass index
(BMI) values [17], to be Spanish or to have been educated in Spain,
and to be free of any other diagnosed disease. Adolescents receiving
pharmacological treatment or diagnosed with anorexia, bulimia or
any other eating disorder except binge eating disorder, were
excluded. All selected adolescents were treated as part of the
EVASYON Study (Development, implementation and evaluation of
the efficacy of a therapeutic programme for adolescents with
overweight and obesity: comprehensive education on nutrition
and physical activity) [18].
The EVASYON project was an intervention study in a cohort of
overweight and obese adolescents. It comprised a long-term
(approximately 13 months) multidisciplinary treatment pro-
gramme based on a calorie-restricted diet (10e40%), increased
physical activity (at least 60 min/day, 5 days a week), psychological
therapy and nutritional education. The maximum energy intake
was 1800 kcal/day for females and 2200 kcal/day for males.
Macronutrient distribution was 50% of energy from carbohydrates,
30% from fat and 20% from proteins. The adolescents were treated
in groups of a maximum of 10 subjects and each group had 20 visits
during the intervention. The treatment comprehended two stages,
an intensive intervention phase (1st to 9th visits) with weekly
checks during the first 2 months, and an extensive intervention
phase (10th to 20th visits) where adolescents were monitored
monthly until the end of programme. The complete and detailed
methodology of the EVASYON Study has been described elsewhere
[18].
2.3. Dietary intake and physical condition
Dietary intake was assessed by applying 72-h dietary record and
a semi-quantitative food-frequency questionnaire, previously
validated. Data of food intake by 72-h dietary record were trans-
formed into food volume/weight (in mL or g). The nutrient con-
sumption was determined using the latest available information in
food-composition tables from Spain. Vitamins and carotenoids
were estimated from the intake of respective food sources.
To evaluate the physical activity, several tests and questionnaire
were used, such as Physical Activity Questionnaire for Adolescentsn plasma antioxidant vitamin levels, adiposity and cardio-metabolic
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strength, 4  10-m shuttle-run, among others. The complete and
detailed methodology has been described elsewhere [18].
2.4. Anthropometry, pubertal development and resting blood
pressure
Body weight (kg) was measured without shoes and with light
clothing to the nearest 0.05 kg using a standard beam balance.
Triceps, biceps, subscapular, suprailiac, thigh and calf skin-fold
thicknesses were measured on the left side of the body to the
nearest 0.2 mm using a Holtain skin-fold calliper. All the anthro-
pometric variables were measured consecutively in triplicate and
averaged. For all the anthropometric measurements, intra-observer
reliability was >95% and inter-observer reliability was >90%.
Pubertal development was assessed in accordance with the 5-
stage system established by Tanner [19]. Each stage describes pu-
bic hair and breast development in girls and pubic hair and genital
development in boys.
Blood pressure was measured using a validated digital auto-
matic blood pressure monitor (Omron M6, Omron Health Care Co.,
Ltd., Kyoto, Japan) in accordance with the International Protocol of
the European Society of Hypertension [20].
2.5. Biochemical and metabolic analysis
Blood was collected by venipuncture after an overnight fast. It
was then centrifuged and aliquots of plasma or serum were stored
at 80 C until analysis.
Total cholesterol, high density lipoprotein (HDL) cholesterol,
triacylglycerols (TAG) and glucose were analysed using an Olympus
AU2700 biochemical autoanalyser (Olympus, Melville, NY, USA).
The coefficients of variance obtained were 2% for total cholesterol,
2% for HDL cholesterol and 3% for TAG. Very-low-density lipopro-
tein (VLDL) cholesterol and low density lipoprotein (LDL) choles-
terol were calculated from existing values for cholesterol, HDL
cholesterol and triglycerides [21]. Apolipoprotein B (apoB) and A1
(apoA1), insulin and C-reactive protein (CRP) were analysed using
the methodology described in full detail elsewhere [18].
2.6. Determination of plasma antioxidant vitamins and carotenoids
Plasma levels of a-tocopherol, retinol, b-carotene and lycopene
were determined at three different periods: before starting treat-
ment, at 2 months and at 6 months of intervention. Analyses were
carried out by Ultra High Performance Liquid Chromatography
(UHPLC). Individual stock standard solutions were prepared for a-
tocopherol, a-tocopherol acetate, retinol and retinyl acetate in
ethanol, while b-carotene and lycopene standard solutions were
prepared in dichloromethane:methanol (2:1). Concentration
ranges for calibration were 5e150 mg/mL (a-tocopherol) and
0.1e5 mg/mL (retinol, b-carotene, lycopene). Sample analysis was
performed as follows: 300 mL of previously vortexed plasma was
de-proteinatedwith 500 mL of internal standardmixture (0.6 mg/mL
retinyl acetate and 17 mg/mL a-tocopherol acetate in ethanol),
vortexed for 1 min and extracted by centrifugation (4000 rpm,
5 min, 21e22 C) twice with 1 mL of hexane. The organic phase
obtained was filtered using Acrodisc 13mm Syringe Filter equipped
with 0.2 mm GHP membranes, and was then evaporated to dryness
under nitrogen atmosphere at 35 C. The residues were recon-
stituted to 50 mL with a solution of dichloromethane:methanol
(2:1) and vortexed for 15 s. Chromatographic determination was
performed using an Acquity Ultra Performance Liquid Chromato-
graphic System (UPLC) (Waters, Milford, MA, USA) equipped with a
binary solvent delivery module and a 2996 Photodiode Array (PDA)Please cite this article in press as: Guerendiain M, et al., Relation betwee
profile in adolescents: Effects of a multidisciplinary obesity programme,detector. An Acquity UPLC BEH C18 column (2.1 mm i.d.  50 mm,
1.7 mm particle size) (Waters, Milford, MA, USA) and an Acquity
UPLC BEH C18 Van Guard Pre-column (2.1 mm i.d.  5 mm, 1.7 mm
particle size) (Waters, Milford, MA, USA) were used. Column and
autosampler temperatures were 30 C and 10 C, respectively.
Methanol was used as mobile phase at a flow rate of 0.6 mL/min.
Injection volume was 3 mL and total run time 3 min. The wave-
lengths selected were 325, 292 and 450 nm for retinol, tocopherol
and carotenoid analysis, respectively. The validity of the UHPLC
method was assessed by including serum calibration standards and
bi-level serum controls (Chromsystems, Munich, Germany).
Method validation results are presented in Table 1.
2.7. Statistical analysis
Results are presented as means ± standard deviation (SD) or
standard error of the mean (SEM). SPSS 20.0 (SPSS Inc, Chicago, IL,
USA) was used for statistical analyses. Changes in clinical or
biochemical parameters and plasma lipid-soluble antioxidant
vitamin and carotenoid levels were analysed by general linear
models using Bonferroni post hoc correction. To evaluate the as-
sociation between changes in antioxidant vitamins and carotenoids
and anthropometric indicators of adiposity, blood pressure and
biochemical parameters at 2 and 6 months of intervention, linear
regression models were applied, adjusted for age, sex, body mass
index standard deviation score (SDS-BMI) and Tanner stages at
baseline, changes in intake of energy and corresponding vitamins
or carotenoids at 6 months respect to baseline, and degree of
physical activity. General linear models were also carried out to
examine the differences between changes in clinical and
biochemical parameters and changes in plasma vitamin and
carotenoid levels at 6 months of intervention in the different
weight loss groups, controlling for potential confounding factors
(sex, age, SDS-BMI, Tanner stage and the corresponding variable at
baseline, changes in intake of energy and corresponding vitamins
or carotenoids at 6 months, and degree of physical activity). To
determine whether changes in parameters studied were significant
in each group of weight loss, estimated marginal means were used.
For all analyses, two-sided significance was determined at a
P < 0.05.
3. Results
The clinical and biochemical characteristics, physical condition
and dietary intake of adolescents, at baseline and at 2 and 6months
of treatment, are given in Table 2. Participants' mean age and
baseline body mass index (BMI) were 14.09 ± 1.21 years old and
31.4 ± 0.49 kg/m2, respectively; 46% were males and 54% females. It
was found that weight and anthropometric indicators of total
adiposity [BMI, SDS-BMI, body fat and fat mass index (FMI)] and
central adiposity (waist circumference) decreased significantly
during the 6 months of intervention (P < 0.001), whereas the per-
centage of fat free mass (FFM) increased (P < 0.001). Systolic (SBP)
and diastolic blood pressure (DBP) improved after 2 months of
treatment (P ¼ 0.002 and <0.001, respectively), subsequently
remaining unchanged until the end of treatment. Most of the
biochemical parameters (glucose, insulin, cholesterol, HDL choles-
terol, LDL cholesterol, apoA1, apoB and CRP) decreased during the
intensive intervention phase (P < 0.05). However, the TAG and
apolipoprotein B/apolipoprotein A1 (apoB/apoA1) ratio only
changed at the end of the programme (P ¼ 0.001), showing values
lower than those measured at baseline and 2 months of intensive
treatment. During the extensive intervention phase, some of the
parameters which had decreased during the intensive period, such
as cholesterol, HDL cholesterol and apoA1, became higher withn plasma antioxidant vitamin levels, adiposity and cardio-metabolic
Clinical Nutrition (2015), http://dx.doi.org/10.1016/j.clnu.2015.11.001
Table 1
Parameters of UHPLC method validation for lipid-soluble vitamins and carotenoids.
Analytes Repeatability (n ¼ 10) Reproducibility (n ¼ 20) Linearity LOD (ng/mL) LOQ (ng/mL) Recovery (%)
Means ± SD (mg/mL) CV (%) Means ± SD (mg/mL) CV (%) Equation r2
a-Tocopherol 18.87 ± 0.20 1.04 18.98 ± 0.36 1.89 y ¼ 0.0196x þ 0.0166 0.9999 29 99 103
Retinol 0.62 ± 0.01 1.89 0.61 ± 0.03 4.28 y ¼ 0.2559x  0.0105 1 1.6 5.2 97
Lycopene 0.15 ± 0.01 4.22 0.15 ± 0.01 6.96 y ¼ 0.4508x þ 0.006 0.9998 2.2 7.3 92
b-Carotene 0.09 ± 0.00 4.62 0.08 ± 0.01 6.12 y ¼ 0.5581x þ 0.007 0.9999 1.8 6.1 91
CV, coefficient of variation; LOD, limit of detection; LOQ, limit of quantification.
M. Guerendiain et al. / Clinical Nutrition xxx (2015) 1e94respect to 2 months (P < 0.001), but did not return to the baseline
values. Regarding to physical condition, it was observed that agility
and cardiorespiratory endurance improved from 2 months
(P < 0.001), whilst handgrip strength increased significantly at the
end of intervention (P < 0.001). On the other hand, the intake of
energy, carbohydrates, proteins, lipids, vitamin A and vitamin E
decreased (P < 0.001), whereas b-carotene intake enhanced
(P ¼ 0.014) and lycopene tended to increase (P ¼ 0.064).
Changes in plasma a-tocopherol, retinol, lycopene and b-caro-
tene levels during treatment are presented in Fig. 1. Values are
expressed as concentration, and also applying a lipid correction [6]
by dividing the concentration by the sum of cholesterol and TAG. It
was observed that lipid-corrected (LC) retinol increased signifi-
cantly at 2 months of treatment (P < 0.05), whereas LC b-carotene
(P ¼ 0.001) and LC a-tocopherol (P < 0.001) were significantlyTable 2
Characteristics of study population at baseline and during the weight loss treatment.
Characteristics N Baseline
Clinical parameters
Weight (kg) 106 85.7 ± 1.66A
BMI (kg/m2) 106 31.4 ± 0.49A
SDS-BMI 106 2.80 ± 0.05A
Waist circumference (cm) 97 99.0 ± 1.24A
Body fat (%) 93 35.8 ± 0.47A
Body fat (kg) 92 30.8 ± 0.80A
FMI (kg/m2) 90 11.2 ± 0.28A
FFM (%) 93 64.2 ± 0.47A
Systolic blood pressure (mm Hg) 80 123.4 ± 1.60A
Diastolic blood pressure (mm Hg) 80 72.6 ± 1.29A
Biochemical parameters
Glucose (mmol/L) 97 4.63 ± 0.04A
Insulin (mUI/mL) 20 18.8 ± 3.00A
Cholesterol (mmol/L) 106 4.01 ± 0.06A
HDL-cholesterol (mmol/L) 104 1.15 ± 0.03A
LDL-cholesterol (mmol/L) 104 2.34 ± 0.06A
Triacylglycerol (mmol/L) 106 1.01 ± 0.05A
Apolipoprotein A1 (mg/dL) 73 117.14 ± 2.16A
Apolipoprotein B (mg/dL) 73 69.93 ± 2.06A
ApoB/apoA1 ratio 73 0.62 ± 0.19A,B
C-reactive protein (mg/L) 58 3.26 ± 0.43A
Physical condition
Hand grip strength (kg) 107 29.12 ± 7.78A
Agility (seconds) 106 13.62 ± 1.53A
Cardiorespiratory endurance (periods) 98 3.07 ± 1.52A
Dietary intake
Energy (kcal/d) 113 3336.87 ± 1613.99
Carbohydrates (g/d) 113 362.9 ± 181.09A
Proteins (g/d) 113 130.81 ± 59.27A
Lipids (g/d) 113 151.04 ± 84.42A
Total fibre (g/d) 113 27.05 ± 13.01A
Vitamin A (mg/d)a 90 486.26 ± 601.23A
Vitamin E (mg/d)a 100 11.44 ± 10.81A
b-Carotene (mg/d)a 108 3724.94 ± 4602.29
Lycopene (mg/d)a 107 119.29 ± 168.66A
Results expressed as means ± SEM. Means in a row with different superscript letters a
correction). BMI, bodymass index; SDS-BMI, BMI standard deviation score; FMI, fat mass i
cholesterol, low-density lipoprotein cholesterol; ApoB/apoA1 ratio, apolipoprotein B/apo
a Determined from intake of dietary sources.
Please cite this article in press as: Guerendiain M, et al., Relation betwee
profile in adolescents: Effects of a multidisciplinary obesity programme,higher in the final stage of the treatment. LC lycopene levels did not
change during the intervention.
Table 3 shows the associations between the changes in plasma
antioxidant vitamin and carotenoid levels and the changes in
several clinical and biochemical parameters at 2 and 6 months, in
relation to baseline values. Since LC lycopene remained unaltered
during the treatment, its correlations with other parameters have
not been explored. As shown in Fig. 1, the changes LC retinol levels
were significant at 2 months of treatment. Thus, the increase in LC
retinol was associated with a reduction in cholesterol and TAG
(P < 0.001).
The changes in LC a-tocopherol and LC b-carotene levels were
significant at 6 months of intervention (see Fig. 1). Hence, the in-
crease in LC a-tocopherol was inversely related toweight (P < 0.01),
BMI (P < 0.01), SDS-BMI (P < 0.01), body fat (P < 0.01), FMI2 months 6 months P
81.5 ± 1.57B 80.2 ± 1.58C <0.001
29.7 ± 0.47B 28.8 ± 0.49C <0.001
2.55 ± 0.06B 2.35 ± 0.07C <0.001
95.8 ± 1.16B 90.8 ± 1.17C <0.001
34.3 ± 0.50B 33.2 ± 0.60C <0.001
28.1 ± 0.76B 26.8 ± 0.82C <0.001
10.2 ± 0.28B 9.6 ± 0.30C <0.001
65.7 ± 0.50B 66.8 ± 0.60C <0.001
118.7 ± 1.45B 118.0 ± 1.45B 0.002
67.4 ± 1.23B 67.1 ± 1.04B <0.001
4.51 ± 0.05B 4.54 ± 0.05A,B 0.012
14.5 ± 1.46B 14.8 ± 1.58B 0.047
3.67 ± 0.07B 3.77 ± 0.07C <0.001
1.05 ± 0.03B 1.14 ± 0.03C <0.001
2.14 ± 0.06B 2.17 ± 0.06B <0.001
0.91 ± 0.05A 0.86 ± 0.04B 0.001
106.64 ± 1.86B 112.79 ± 2.03C <0.001
65.32 ± 2.04B 65.09 ± 2.32B <0.001
0.63 ± 0.18A 0.59 ± 0.19B 0.002
2.12 ± 0.23B 2.12 ± 0.20B 0.001
29.82 ± 8.10A 30.51 ± 8.08B <0.001
13.03 ± 1.50B 13.01 ± 1.28B <0.001
3.56 ± 1.82B 3.77 ± 1.80B <0.001
A e 2202.02 ± 625.56B <0.001
e 249.38 ± 74.33B <0.001
e 108.55 ± 30.45B <0.001
e 85.30 ± 34.83B <0.001
e 26.26 ± 9.91A 0.553
e 197.15 ± 314.49B <0.001
e 6.03 ± 4.53B <0.001
A e 4997.34 ± 3882.13B 0.014
e 152.86 ± 160.73A 0.064
re significantly different, P < 0.05 (general linear model with Bonferroni post hoc
ndex; FFM, fat freemass; HDL-cholesterol, high-density lipoprotein cholesterol; LDL-
lipoprotein A1 ratio.
n plasma antioxidant vitamin levels, adiposity and cardio-metabolic
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Fig. 1. Lipid-soluble antioxidant vitamin (A) and carotenoid (B) plasma levels. Values expressed as means ± SD. The scale for LC a-tocopherol, retinol and LC retinol is 0e6; for a-
tocopherol 5 to 45; for lycopene and b-carotene 0e0.5; and for LC lycopene and LC b-carotene 0e0.3. Means in a row with different superscript letters are significantly different,
P < 0.05 (general linear model with Bonferroni post hoc correction). LC, lipid-corrected; a-tocopherol, n ¼ 103; retinol, n ¼ 103; lycopene, n ¼ 102; b-carotene, n ¼ 101; LC a-
tocopherol, n ¼ 85; LC retinol, n ¼ 85; LC lycopene, n ¼ 84; LC b-carotene, n ¼ 83.
M. Guerendiain et al. / Clinical Nutrition xxx (2015) 1e9 5(P < 0.01), cholesterol (P < 0.001), LDL cholesterol (P < 0.05) and
TAG (P < 0.001). Conversely, the relationship observed between LC
a-tocopherol and FFM was positive (P < 0.01). LC b-carotene con-
centration showed a significant and negative association with in-
sulin (P < 0.01) and HDL cholesterol (P < 0.001).
In our study, the degree of weight loss in adolescents during the
programme proposed was defined as the decrease in SDS-BMI.
Changes in clinical and biochemical parameters, antioxidant vita-
mins and carotenoids, defined as a reduction in SDS-BMI at 6
months follow up, are given in Fig. 2. Adolescents were divided into
three groups according to changes in SDS-BMI between baseline
and 6 months of intervention. The SDS-BMI decrease > 0.5 group
showed the largest decrease in anthropometric indicators of
adiposity (P < 0.001) and biochemical parameters (P < 0.05),
whereas the SDS-BMI decrease < 0.25 group presented the lowest
reduction, or the opposite behaviour (Fig. 2A and B, respectively).
Conversely, the highest increase in FFM was observed in the SDS-
BMI decrease > 0.5 group and the lowest in the SDS-BMIPlease cite this article in press as: Guerendiain M, et al., Relation betwee
profile in adolescents: Effects of a multidisciplinary obesity programme,decrease < 0.25 group (P < 0.001). No differences were found be-
tween the weight loss groups in SBP, DBP, glucose, insulin, HDL
cholesterol, CRP, apoA1 and the apoB/apoA1 ratio.
On the other hand, by comparing the baseline values with those
obtained at 6months of treatment in the same group of weight loss,
it was found that the clinical and biochemical parameters,
excepting insulin and HDL cholesterol, changed significantly in the
SDS-BMI decrease > 0.5 group (P < 0.05). Should be noted that the
indicators of general adiposity decreased and the FFM increased
significantly even in the adolescents that had a lower weigh loss
(SDS-BMI decrease < 0.25) (P < 0.05).
In relation to antioxidant vitamin and carotenoid levels at 6
months (Fig. 2C), it was observed that the changes in LC retinol
were independent to degree of weight loss, because there were no
differences between groups or in the same group.When comparing
the vitamin levels at 6 months with baseline values for each weight
loss group, it was observed that LC b-carotene (P¼ 0.034) and LC a-
tocopherol (P ¼ 0.001) increased significantly in the adolescentsn plasma antioxidant vitamin levels, adiposity and cardio-metabolic
Clinical Nutrition (2015), http://dx.doi.org/10.1016/j.clnu.2015.11.001
Table 3
Association between changes in plasma antioxidant vitamin and carotenoid levels and clinical and biochemical parameters at 2 and 6 months of treatment.
Parametersa 2 months 6 months
a-Tocopherola,b Retinola,b b-Carotenea,b a-Tocopherola,b Retinola,b b-Carotenea,b
Weight (kg) 0.162 0.061 0.174 ¡0.347** 0.146 0.039
BMI (kg/m2) 0.193 0.154 0.183 ¡0.380** 0.174 0.088
SDS-BMI 0.153 0.103 0.161 ¡0.398** 0.141 0.112
WC (cm) 0.243 0.107 0.084 0.164 0.064 0.151
Body fat (%) 0.252 0.216 0.012 ¡0.444** 0.162 0.243
Body fat (kg) 0.302 0.133 0.147 ¡0.412** 0.147 0.101
FMI (kg/m2) 0.284 0.066 0.128 ¡0.427** 0.174 0.151
FFM (%) 0.302 0.216 0.012 0.444** 0.162 0.243
SBP (mm Hg) 0.104 0.081 0.030 0.019 0.217 0.019
DBP (mm Hg) 0.272 0.046 0.192 0.215 0.084 0.254
Glucose (mmol/L) 0.132 0.238 0.049 0.179 0.194 0.056
Insulin (mUI/mL) 0.069 0.025 0.523 0.199 0.219 ¡0.778**
Cholesterol (mmol/L) 0.495** ¡0.404* 0.156 ¡0.482*** 0.541** 0.233
HDL-C (mmol/L) 0.220 0.119 0.288 0.225 0.188 ¡0.526***
LDL-C (mmol/L) 0.418* 0.266 0.244 0.329* 0.403* 0.066
TAG (mmol/L) 0.368* ¡0.587*** 0.016 ¡0.505*** 0.520** 0.084
ApoA1 (mg/dL) 0.116 0.111 0.085 0.121 0.137 0.226
ApoB (mg/dL) 0.344 0.269 0.281 0.167 0.455* 0.140
ApoB/apoA1 0.152 0.213 0.176 0.122 0.513* 0.058
CRP (mg/L) 0.318 0.235 0.071 0.129 0.003 0.133
Standardised regression coefficients adjusted for age, sex, SDS-BMI and Tanner stages at baseline, changes in intake of energy and corresponding vitamins or carotenoids at 6
months, and degree of physical activity; *P < 0.05, **P < 0.01, ***P < 0.001 (linear regression model).
BMI (body mass index), n ¼ 49; SDS-BMI (standard deviation score-BMI), n ¼ 49; WC (waist circumference), n ¼ 49; FMI (fat mass index), n ¼ 48; FFM (fat free mass), n ¼ 48;
SBP (systolic blood pressure), n¼ 44; DBP (diastolic blood pressure), n¼ 44; HDL-C (high-density lipoprotein cholesterol), n¼ 51; LDL-C (low-density lipoprotein cholesterol),
n¼ 51; TAG (triacylglycerol), n¼ 51; ApoA1 (apolipoprotein A1), n¼ 36; ApoB (apolipoprotein B), n¼ 36; ApoB/apoA1 (apolipoprotein B/apolipoprotein A1 ratio), n¼ 36; CRP
(C-reactive protein), n ¼ 36. Weight, n ¼ 49; body fat percentage, n ¼ 48; body fat kg, n ¼ 48; glucose, n ¼ 51; cholesterol, n ¼ 51; insulin, n ¼ 15.
a Changes in parameters between the baseline and 2 or 6 months of treatment.
b Lipid-corrected values.
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LC lycopene improved in SDS-BMI decrease 0.25e0.5 group
(P ¼ 0.019).
4. Discussion
Since plasma lipid-soluble vitamins and carotenoids are carried
by lipoproteins [11,16] and given the relationship detected, in our
study, between plasma lipids and changes in vitamin or carotenoid
concentrations (data not shown), the effects of a-tocopherol,
retinol, b-carotene and lycopene on biochemical and clinical pa-
rameters were analysed using their lipid-corrected levels [6].
Previous studies have reported that obese children present
higher lipid concentrations [3,6] and peroxidation [5] than their
normal weight counterparts. Antioxidant vitamins and carotenoids
reduce lipid peroxidation and enhance LDL cholesterol resistance to
oxidation [11,12]. In turn, there is evidence that whether adjusted
and unadjusted for lipids, both b-carotene and a-tocopherol levels
are lower in obese children [6]. The negative association confirmed,
in this research, between changes in lipid concentration and
changes in LC a-tocopherol, LC retinol and LC b-carotene suggests
that the increase in plasma antioxidant vitamins and carotenoids
may protect obese adolescents against oxidative stress.
In agreement with other studies, in which obese adults [23] and
adolescents [24] were subjected to different dietary regimes, we
found that HDL cholesterol decreased in the first stage of treatment.
The subsequent recovery of this and apolipoprotein A1 (apoA1) was
essential because they play an important role in removing the
excess of cholesterol from tissues, consequently exerting an anti-
atherogenic effect [2,22]. Current studies have suggested that the
apoB/apoA1 ratio predicts CVD risk better than any traditional
cholesterol index, such as total cholesterol or LDL cholesterol [25].
Since in this study, the apoB/apoA1 ratio decreased in the last stage
of intervention, a reduction in the participants' risk of CVD could be
reached.Please cite this article in press as: Guerendiain M, et al., Relation betwee
profile in adolescents: Effects of a multidisciplinary obesity programme,Recently, insulin resistance and hyperinsulinemia have
emerged as major concerns in overweight and obese children [3],
since both may lead to impaired glucose tolerance and type-2
diabetes [26]. In addition to obesity itself, hyperinsulinemia and
insulin resistance may play an important role as sources of
oxidative stress [27] and they are related to reduced endogen and
exogen antioxidants [6] in children and adolescents. In the pre-
sent study, the decrease in plasma fasting insulin may be
explained by the increase in b-carotene levels at 6 months of
treatment, which is consistent with the results reported by other
authors [6].
In relation to anthropometric indicators, we obtained inter-
esting results for a-tocopherol, since the increase in LC a-tocoph-
erol levels was associated to decrease in adiposity. These
associations may be attributed to the strong antioxidant capacity of
vitamin E [13,14]. The elevated protein oxidation and lipid peroxi-
dation found in obese adolescents [5] may induce the production of
inflammatory eicosanoids and cytokines [14], which suggests that
improving a-tocopherol concentrations may represent an useful
anti-inflammatory approach. In addition, the role of vitamin E as
regulator of enzymes and gene activity [16] has recently been
discovered. Hence, a-tocopherol may modulate genes with an
important function in endocrine signalling, specifically in glucose
and lipid metabolism [16].
Regarding the degree of weight loss, in previous studies, only
obese children and adolescents with a decrease in SDS-BMI > 0.5
have been observed to present an improved CVD risk factor profile
and intima-media thickness [28], an early marker of atheroscle-
rosis. However, we found a decrease in plasma proatherogenic
lipids also in the SDS-BMI decrease 0.25e0.5 group. In addition, BMI,
body fat and FMI decreased even in the group with lower weight
loss. This suggests that adiposity indicators, especially those of
general adiposity and pro-atherogenic lipids, are more influenced
by degree of weight loss than blood pressure, glucose, CRP and
apolipoproteins. These findings could be useful when settingn plasma antioxidant vitamin levels, adiposity and cardio-metabolic
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Fig. 2. Changes in clinical (A) and biochemical (B) parameters, lipid-soluble antioxidant vitamins and carotenoids (C) according to degree of weight loss. Changes in parameters
between baseline and 6 months as defined by a reduction in BMI standard deviation score (SDS-BMI) at 6 months follow-up. Values expressed as means ± SD. Models were adjusted
for age, sex, SDS-BMI, Tanner stages and corresponding variables at baseline, changes in intake of energy and corresponding vitamins or carotenoids at 6 months, and degree of
physical activity. Means in a row with different superscript letters are significantly different, *statistically significant differences in parameter changes at 6 months of treatment in
relation to baseline, P < 0.05 (general linear model with Bonferroni post hoc correction). Means for glucose, Chol, HDL-C, LDL-C, TAG, APO B/APO A1, LC lycopene and LC b-carotene
were multiplied by a factor of 10. BMI, body mass index; WC, waist circumference; FMI, fat mass index; FFM, fat free mass; SBP, systolic blood pressure; DBP, diastolic blood
pressure; CRP, C-reactive protein; CHOL, cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; TAG, triacylglycerol; APO A1, apoli-
poprotein A1; APO B, apolipoprotein B; APO B/APO A1, apolipoprotein B/apolipoprotein A1 ratio; LC, lipid-corrected. Anthropometry, n ¼ 10/19/23 (for SDS-BMI decrease < 0.25,
SDS-BMI decrease 0.25e0.5 and SDS-BMI decrease > 0.5, respectively); blood pressure, n ¼ 15/23/29; lipid profile and glucose, n ¼ 17/25/33; insulin, n ¼ 4/7/5; apolipoproteins and
CRP, n ¼ 6/10/19; LC a-tocopherol, n ¼ 10/16/22; LC retinol, n ¼ 7/13/20; LC b-carotene, n ¼ 8/17/23 and LC lycopene, n ¼ 10/17/23.
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disorders.
In addition, it is interesting to note that weight losses greater
than 0.5 of SDS-BMI were related to an increase in LC a-tocopherol
and LC b-carotene levels. Furthermore, it was observed that the
adolescents with intermediate decline of SDS-BMI (0.25e0.5)
exhibit an increase in LC lycopene concentration at 6 months. These
interactions were expected because it has been established that
vitamin E and carotenoids may modulate several genes involved in
glucose and lipid metabolism [15,16], fat storage [8] and inflam-
mation in adipose tissue [9].Please cite this article in press as: Guerendiain M, et al., Relation betwee
profile in adolescents: Effects of a multidisciplinary obesity programme,The reduction in adiposity, biochemical parameters and blood
pressure observed in our study population are in line with other
studies on children, showing that weight loss, as determined by a
decrease in BMI or SDS-BMI, leads to an improvement in the CVD
risk factor profile [29]. These results are of great importance since it
has been demonstrated that atherosclerosis is initiated in child-
hood [30]; therefore, the changes observed in subjects' cardio-
metabolic profile in our study might prevent or delay the onset of
the CVD associated with obesity in adulthood.
The main limitation of this study was the absence of a control
group. Consequently, it has not been possible to establish then plasma antioxidant vitamin levels, adiposity and cardio-metabolic
Clinical Nutrition (2015), http://dx.doi.org/10.1016/j.clnu.2015.11.001
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ever, as our initial aim was to analyse the evolution of the different
indicators during the course of treatment and their relationship
with weight loss, we consider the use of baseline values as control
to be acceptable. The majority of the parameters studied showed a
decrease during the intensive phase of treatment. After this phase,
these parameters presented stable values or even experienced an
unexpected increase. Consequently, it might be interesting to
conduct a long-term study in order to evaluate the stability of the
improvements achieved and optimise the duration and intensity of
the programme. The periods established for medical controls
should also be revised, since shorter periods between checks might
favour correct observance of the instructions, especially when
dealing with young population.
The present study has clearly demonstrated that lipid-corrected
antioxidant vitamin and carotenoid levels changed significantly
during the proposed treatment. The increase in lipid-corrected a-
tocopherol, retinol and b-carotene plasma levels was associated
with a reduction in adiposity and a clinically significant improve-
ment in cardio-metabolic profiles.
The increase in lipid-soluble antioxidant vitamin and carotenoid
plasma levels could be useful in childhood obesity treatment, since
lipid-corrected a-tocopherol, b-carotene and lycopene plasma
levels are related to greater weight loss. To our knowledge, no
studies have been published to date which have analysed changes
in lipid-soluble vitamins and carotenoids according to degree of
weight loss. Consequently, we believe that these findings may be
useful to establish unstudied relationships.
Further research is required to confirm the effects of lipid-
soluble antioxidant vitamins and carotenoids on anthropometric
indicators of adiposity, weight loss and cardio-metabolic profile in
diverse populations.
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